Catabasis Pharmaceuticals Stock Price - CATB

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Catabasis Pharmaceuticals Inc CATB NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.01 0.21% 4.76 4.87 4.73 4.73 4.75 10:37:51
Bid Price Ask Price Spread Spread % News
4.75 4.79 0.04 0.84% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
45 10,946 $ 4.76 $ 52,055 116,400 3.60 - 9.76
Last Trade Time Type Quantity Stock Price Currency
10:39:58 20 $ 4.7662 USD

Catabasis Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 55.30M 11.62M $ -25.87M -6.28 - 11.11M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 4.00 4.30%

more financials information »

Catabasis Pharmaceuticals News

Latest CATB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CATB Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.905.224.574.77144,844-0.14-2.86%
1 Month5.636.154.425.00157,771-0.87-15.45%
3 Months7.157.474.425.4181,231-2.39-33.43%
6 Months8.258.904.426.4683,207-3.49-42.3%
1 Year7.109.763.606.05189,990-2.34-32.96%
3 Years48.4055.103.6015.40622,744-43.64-90.17%
5 Years127.40169.603.6019.33464,227-122.64-96.26%

Catabasis Pharmaceuticals Description

Catabasis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted, a linker-drug discovery platform. The company's primary focus is on treatments for rare diseases. Its product pipeline includes CAT-1004, an oral small molecule for the treatment of Duchenne muscular dystrophy, CAT-2054 for the treatment of hypercholesterolemia and CAT-4001 which is used for the treatment of rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.
Your Recent History
NASDAQ
CATB
Catabasis ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191022 14:58:03